Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

TB Alliance is honored to join today's High-Level Meeting hosted by the Indonesian Ministry of Health. Leaders and experts in tuberculosis (TB) have convened to discuss strategies, innovations, and ...

KT&G Corporation ("KT&G" or the "Company") (KRX:033780), announced the 'KT&G Corporate Value-up Plan' on the 7th, that includes their goal of achieving 15% ROE and returning KRW 3.7 trillion to ...

ALT-B4 is Alteogen's proprietary human recombinant hyaluronidase enzyme developed utilizing HybrozymeTM technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are ...

Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

South Korea’s Alteogen (Kosdaq: 196170) has signed an exclusive licensing agreement with Japanese pharmaceutical company ...

Plus, news about Disc Medicine, AlloVir, Kalaris, Travere Therapeutics and Trevena: Daiichi Sankyo, Alteogen to develop subcutaneous version of Enhertu: Daiichi will pay $20 million upfront to the ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Winners received prestigious award in recognition of latest innovations in advancement in life sciences ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...